Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 562-570

  Kharasch, E D ^a   Vangveravong, S ^b   Buck, N ^a   London, A ^a   Kim, T ^a   Blood, J ^a   MacH, R H ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CYTOCHROME P450 3A; DEUTERIUM; KETOCONAZOLE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE SEQUENCE; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; ALFENTANIL; ANESTHETICS, INTRAVENOUS; AREA UNDER CURVE; BEVERAGES; CITRUS PARADISI; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DEUTERIUM; DRUG ADMINISTRATION SCHEDULE; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; HUMANS; INTESTINES; KETOCONAZOLE; LIVER; MALE; MIOSIS; RIFAMPIN; YOUNG ADULT;

EID: 79952990957     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.313     Document Type: Article

References (45)

1. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005).
2. Stevens, J.C. New perspectives on the impact of cytochrome p450 3a expression for pediatric pharmacology. Drug Discov. Today 11, 440-445 (2006).
3. Plant, N. The human cytochrome p450 sub-family: transcriptional regulation, Inter-individual variation and interaction networks. Biochim. Biophys. Acta 1770, 478-488 (2007). (Pubitemid 46136752)
4. Williams, J.A. et al. Comparative metabolic capabilities of CYp3a4, CYp3a5, And CYp3a7. Drug Metab. Dispos. 30, 883-891 (2002).
5. Huang, W. et al. Evidence of significant contribution from CYp3a5 to hepatic drug metabolism. Drug Metab. Dispos. 32, 1434-1445 (2004). (Pubitemid 39564564)
6. Watkins, P.B. Noninvasive tests of CYp3a enzymes. Pharmacogenetics 4, 171-184 (1994). (Pubitemid 24269821)
7. Benet, L.Z. There are no useful CYp3a probes that quantitatively predict the in vivo kinetics of other CYp3a substrates and no expectation that one will be found. Mol. Interv. 5, 79-83 (2005). (Pubitemid 40590507)
8. Kharasch, E.D., Thummel, K.E. & Watkins, P.B. CYp3a probes can quantitatively predict the in vivo kinetics of other CYp3a substrates and can accurately assess CYp3a induction and inhibition. Mol. Interv. 5, 151-153 (2005). (Pubitemid 41018270)
9. Liu, Y.T., Hao, H.P., Liu, C.X., Wang, G.J. & Xie, H.G. Drugs as CYp3a probes, Inducers, And inhibitors. Drug Metab. Rev. 39, 699-721 (2007).
10. Kirwan, C., Macphee, I. & Philips, B. Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, A flawed but useful tool for clinical investigation of CYp3a activity? Expert Opin. Drug Metab. Toxicol. 6, 761-771 (2010).
11. Zaigler, M., Tantcheva-poór, I. & Fuhr, U. Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int. J. Clin. Pharmacol. Ther. 38, 1-9 (2000). (Pubitemid 30048654)
12. Dahl, M.L. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet. 41, 453-470 (2002).
13. Kharasch, E.D., Walker, A., Hoffer, C., & Sheffels, P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome p450 3a activity: noninvasive assessment using pupillary miosis. Clin. Pharmacol. Ther. 76, 452-466 (2004). (Pubitemid 39469869)
14. Kharasch, E.D. et al. Influence of CYp3a5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome p4503a probes alfentanil and midazolam. Clin. Pharmacol. Ther. 82, 410-426 (2007). (Pubitemid 47414348)
15. Rogers, J.F., Rocci, M.L. Jr, Haughey, D.B. & Bertino, J.S. Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome p4503a activity. Clin. Pharmacol. Ther. 73, 153-158 (2003). (Pubitemid 36269666)
16. Kharasch, E.D. et al. The role of cytochrome p450 3a4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 87, 36-50 (1997). (Pubitemid 27438621)
17. Kharasch, E.D., Russell, M., Garton, K., Lentz, G., Bowdle, T.A. & Cox, K. Assessment of cytochrome p450 3a4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 87, 26-35 (1997). (Pubitemid 27438620)
18. Kharasch, E.D., Jubert, C., Senn, T., Bowdle, T.A. & Thummel, K.E. Intraindividual variability in male hepatic CYp3a4 activity assessed by alfentanil and midazolam clearance. J. Clin. Pharmacol. 39, 664-669 (1999).
19. Phimmasone, S. & Kharasch, E.D. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome p450 3a4 (CYp3a4) activity in humans. Clin. Pharmacol. Ther. 70, 505-517 (2001). (Pubitemid 34008407)
20. Kharasch, E.D., Hoffer, C., Walker, A. & Sheffels, P. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome p4503a activity. Clin. Pharmacol. Ther. 73, 199-208 (2003). (Pubitemid 36269671)
21. Kharasch, E.D., Walker, A., Hoffer, C. & Sheffels, P. Evaluation of first-pass cytochrome p4503a (CYp3a) and p-glycoprotein activities using alfentanil and fexofenadine in combination. J. Clin. Pharmacol. 45, 79-88 (2005).
22. Chaobal, H.N. & Kharasch, E.D. Single-point sampling for assessment of constitutive, Induced and inhibited cytochrome p450 3a activity with alfentanil or midazolam. Clin. Pharmacol. Ther. 78, 529-539 (2005).
23. Kharasch, E.D., Walker, A., Hoffer, C. & Sheffels, P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYp3a activity. J. Clin. Pharmacol. 45, 1187-1197 (2005). (Pubitemid 41361919)
24. Kharasch, E.D., Bedynek, P.S., Walker, A., Whittington, D. & Hoffer, C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: ii. Ritonavir effects on CYp3a and p-glycoprotein activities. Clin. Pharmacol. Ther. 84, 506-512 (2008).
25. Kharasch, E.D., Walker, A., Whittington, D., Hoffer, C. & Bedynek, P.S. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome p4503a (CYp3a) activity. Drug Alcohol Depend. 101, 158-168 (2009).
26. Kharasch, E.D., Hoffer, C., Whittington, D., Walker, A. & Bedynek, P.S. Methadone pharmacokinetics are independent of cytochrome p4503a (CYp3a) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 110, 660-672 (2009).
27. Lin, Y.S. et al. In-vivo phenotyping for CYp3a by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11, 781-791 (2001). (Pubitemid 33151513)
28. Zhu, B., Ou-Yang, D.S., Cheng, Z.N., Huang, S.L. & Zhou, H.H. Single plasma sampling to predict oral clearance of CYp3a probe midazolam. Acta Pharmacol. Sin. 22, 634-638 (2001). (Pubitemid 32656493)
29. Kim, J.S. et al. Limited sampling strategy to predict aUC of the CYp3a phenotyping probe midazolam in adults: application to various assay techniques. J. Clin. Pharmacol. 42, 376-382 (2002). (Pubitemid 34259770)
30. Rogers, J.F. et al. Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J. Clin. Pharmacol. 42, 1079-1082 (2002).
31. Lee, L.S., Bertino, J.S. Jr & Nafziger, A.N. Limited sampling models for oral midazolam: midazolam plasma concentrations, Not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, Accurately predicts aUC as a biomarker of CYp3a activity. J. Clin. Pharmacol. 46, 229-234 (2006). (Pubitemid 43146452)
32. Krupka, E. et al. Probe of CYp3a by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur. J. Clin. Pharmacol. 62, 653-659 (2006). (Pubitemid 44127995)
33. Penzak, S.R., Busse, K.H., Robertson, S.M., Formentini, E., Alfaro, R.M. & Davey, R.T. Jr. Limitations of using a single postdose midazolam concentration to predict CYp3a-mediated drug interactions. J. Clin. Pharmacol. 48, 671-680 (2008). (Pubitemid 351713155)
34. Browne, T.R. Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages. Clin. Pharmacokinet. 18, 423-433 (1990). (Pubitemid 20183886)
35. Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O'Mara, E.M. Jr & Hall, S.D. The contribution of intestinal and hepatic CYp3a to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133-143 (1998). (Pubitemid 28423848)
36. Gorski, J.C. et al. The effect of age, Sex, And rifampin administration on intestinal and hepatic cytochrome p450 3a activity. Clin. Pharmacol. Ther. 74, 275-287 (2003). (Pubitemid 37083103)
37. Quinney, S.K., Haehner, B.D., Rhoades, M.B., Lin, Z., Gorski, J.C. & Hall, S.D. Interaction between midazolam and clarithromycin in the elderly. Br. J. Clin. Pharmacol. 65, 98-109 (2008). (Pubitemid 350265166)
38. Lee, J.I., Chaves-Gnecco, D., Amico, J.A., Kroboth, P.D., Wilson, J.W. & Frye, R.F. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome p450 3a phenotyping. Clin. Pharmacol. Ther. 72, 718-728 (2002). (Pubitemid 36021011)
39. Meuldermans, W. et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 69, 527-534 (1988).
40. Kharasch, E.D., Bedynek, P.S., Park, S., Whittington, D., Walker, A. & Hoffer, C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: i. Evidence against CYp3a mediation of methadone clearance. Clin. Pharmacol. Ther. 84, 497-505 (2008).
41. Ohnhaus, E.E., Breckenridge, A.M. & Park, B.K. Urinary excretion of 6 betahydroxycortisol and the time course measurement of enzyme induction in man. Eur. J. Clin. Pharmacol. 36, 39-46 (1989). (Pubitemid 19052008)
42. Venkatesan, K. Pharmacokinetic drug interactions with rifampicin. Clin. Pharmacokinet. 22, 47-65 (1992).
43. Veronese, M.L. et al. Exposure-dependent inhibition of intestinal and hepatic CYp3a4 in vivo by grapefruit juice. J. Clin. Pharmacol. 43, 831-839 (2003). (Pubitemid 36886103)
44. Culm-Merdek, K.E. et al. Effect of extended exposure to grapefruit juice on cytochrome p450 3a activity in humans: comparison with ritonavir. Clin. Pharmacol. Ther. 79, 243-254 (2006).
45. Klees, T.M., Sheffels, P., Dale, O. & Kharasch, E.D. Metabolism of alfentanil by cytochrome p4503a (CYp3a) enzymes. Drug Metab. Dispos. 33, 303-311 (2005). (Pubitemid 40279928)